Is MLTX or TNGX more profitable?

Tango Therapeutics' return on equity of -25.75% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% Tango Therapeutics N/A -25.75% -23.36%

Does the media favor MLTX or TNGX?

In the previous week, Tango Therapeutics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Tango Therapeutics and 2 mentions for MoonLake Immunotherapeutics. Tango Therapeutics' average media sentiment score of 0.89 beat MoonLake Immunotherapeutics' score of 0.67 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CELC or MLTX?

Celcuity is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A

Is CELC or MLTX more profitable?

MoonLake Immunotherapeutics' return on equity of -82.53% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Does the media refer more to CELC or MLTX?

In the previous week, Celcuity had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Celcuity and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Celcuity's score of 0.43 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, MLTX or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is MLTX or ELVN more profitable?

Enliven Therapeutics' return on equity of -18.55% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% Enliven Therapeutics N/A -18.55% -18.09%

Does the media refer more to MLTX or ELVN?

In the previous week, Enliven Therapeutics had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for Enliven Therapeutics and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Enliven Therapeutics' score of 0.49 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MLTX or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% Amylyx Pharmaceuticals N/A -52.92% -48.53%

MoonLake Immunotherapeutics (MLTX) Competitors

$12.90 -0.48 (-3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$12.92 +0.01 (+0.12%)

As of 07:57 PM Eastern

Compare

MLTX vs. IOVA, TNGX, CELC, ELVN, and AMLX

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MoonLake Immunotherapeutics's main competitors and comparable companies include Iovance Biotherapeutics (IOVA), Tango Therapeutics (TNGX), Celcuity (CELC), Enliven Therapeutics (ELVN), and Amylyx Pharmaceuticals (AMLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MoonLake Immunotherapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Iovance Biotherapeutics presently has a consensus price target of $9.11, suggesting a potential downside of 10.59%. MoonLake Immunotherapeutics has a consensus price target of $24.57, suggesting a potential upside of 90.48%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

MoonLake Immunotherapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	17.52	-$390.98M	-$0.73	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 12 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 14 mentions for Iovance Biotherapeutics and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Iovance Biotherapeutics' score of 0.55 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Iovance Biotherapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Summary

MoonLake Immunotherapeutics beats Iovance Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Tango Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Tango Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Tango Therapeutics	$62.38M	66.09	-$101.59M	-$0.85	N/A

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Tango Therapeutics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Tango Therapeutics and 2 mentions for MoonLake Immunotherapeutics. Tango Therapeutics' average media sentiment score of 0.89 beat MoonLake Immunotherapeutics' score of 0.67 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics' return on equity of -25.75% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Tango Therapeutics	N/A	-25.75%	-23.36%

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, indicating a potential upside of 90.48%. Tango Therapeutics has a consensus target price of $43.46, indicating a potential upside of 77.76%. Given MoonLake Immunotherapeutics' higher possible upside, equities research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tango Therapeutics beats MoonLake Immunotherapeutics on 10 of the 13 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Celcuity currently has a consensus target price of $154.75, suggesting a potential upside of 93.46%. MoonLake Immunotherapeutics has a consensus target price of $24.57, suggesting a potential upside of 90.48%. Given Celcuity's stronger consensus rating and higher possible upside, equities analysts plainly believe Celcuity is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

Celcuity has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Celcuity had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Celcuity and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Celcuity's score of 0.43 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Celcuity is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

MoonLake Immunotherapeutics' return on equity of -82.53% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Summary

Celcuity beats MoonLake Immunotherapeutics on 6 of the 11 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Enliven Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, suggesting a potential upside of 90.48%. Enliven Therapeutics has a consensus price target of $75.00, suggesting a potential upside of 62.73%. Given MoonLake Immunotherapeutics' higher possible upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Enliven Therapeutics had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for Enliven Therapeutics and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Enliven Therapeutics' score of 0.49 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enliven Therapeutics' return on equity of -18.55% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Summary

Enliven Therapeutics beats MoonLake Immunotherapeutics on 7 of the 12 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Amylyx Pharmaceuticals?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Amylyx Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Amylyx Pharmaceuticals' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Amylyx Pharmaceuticals	$87.37M	39.02	-$144.74M	-$1.43	N/A

Amylyx Pharmaceuticals' return on equity of -52.92% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

MoonLake Immunotherapeutics currently has a consensus price target of $24.57, suggesting a potential upside of 90.48%. Amylyx Pharmaceuticals has a consensus price target of $38.86, suggesting a potential upside of 26.98%. Given MoonLake Immunotherapeutics' higher possible upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	N/A	13.95	274.58	25.69
Price / Sales	N/A	1,357.85	639.38	80.65
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	3.02	15.30	10.44	6.32
Net Income	-$227.32M	-$22.82M	$3.49B	$359.73M
7 Day Performance	3.53%	-0.22%	0.51%	1.35%
1 Month Performance	-18.15%	-6.06%	-3.38%	-3.68%
1 Year Performance	-75.45%	34.37%	16.04%	5.56%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	2.3354 of 5 stars	$12.90 -3.6%	$24.57 +90.5%	-75.7%	$1.14B	N/A	N/A	130
IOVA Iovance Biotherapeutics	1.5565 of 5 stars	$9.06 -2.1%	$8.89 -1.9%	+401.9%	$4.11B	$263.50M	N/A	975
TNGX Tango Therapeutics	2.8419 of 5 stars	$23.95 -2.4%	$43.46 +81.5%	+242.7%	$4.04B	$53.81M	N/A	137
CELC Celcuity	2.7278 of 5 stars	$81.56 -2.4%	$154.55 +89.5%	+60.2%	$3.99B	N/A	N/A	155
ELVN Enliven Therapeutics	2.2671 of 5 stars	$53.22 -2.2%	$75.00 +40.9%	+141.9%	$3.90B	N/A	N/A	67	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. IOVA, TNGX, CELC, ELVN, and AMLX

How does MoonLake Immunotherapeutics compare to Iovance Biotherapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Tango Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Celcuity?

Summary

How does MoonLake Immunotherapeutics compare to Enliven Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. IOVA, TNGX, CELC, ELVN, and AMLX

How does MoonLake Immunotherapeutics compare to Iovance Biotherapeutics?

Do analysts rate IOVA or MLTX?

Which has better earnings & valuation, IOVA or MLTX?

Do institutionals and insiders hold more shares of IOVA or MLTX?

Does the media refer more to IOVA or MLTX?

Is IOVA or MLTX more profitable?

Which has more volatility & risk, IOVA or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Tango Therapeutics?

Which has better valuation and earnings, MLTX or TNGX?

Which has more risk & volatility, MLTX or TNGX?

Does the media favor MLTX or TNGX?

Is MLTX or TNGX more profitable?

Do analysts rate MLTX or TNGX?

Do institutionals & insiders believe in MLTX or TNGX?

Summary

How does MoonLake Immunotherapeutics compare to Celcuity?

Do analysts prefer CELC or MLTX?

Which has more risk & volatility, CELC or MLTX?

Does the media refer more to CELC or MLTX?

Do institutionals and insiders hold more shares of CELC or MLTX?

Which has preferable valuation & earnings, CELC or MLTX?

Is CELC or MLTX more profitable?

Summary

How does MoonLake Immunotherapeutics compare to Enliven Therapeutics?

Do analysts prefer MLTX or ELVN?

Does the media refer more to MLTX or ELVN?

Do insiders and institutionals hold more shares of MLTX or ELVN?

Is MLTX or ELVN more profitable?

Which has higher earnings & valuation, MLTX or ELVN?

Which has more risk & volatility, MLTX or ELVN?

Summary

How does MoonLake Immunotherapeutics compare to Amylyx Pharmaceuticals?

Which has more risk & volatility, MLTX or AMLX?

Does the media favor MLTX or AMLX?

Which has better valuation and earnings, MLTX or AMLX?

Is MLTX or AMLX more profitable?

Do analysts recommend MLTX or AMLX?

Do insiders & institutionals have more ownership in MLTX or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools